Brett A King1, Natasha Atanaskova Mesinkovska2, Brittany Craiglow3, Chesahna Kindred4, Justin Ko5, Amy McMichael6, Jerry Shapiro7, Carolyn Goh8, Paradi Mirmirani9, Antonella Tosti10, Maria Hordinsky11, Kathie P Huang12, Leslie Castelo-Soccio13, Wilma Bergfeld14, Amy S Paller15, Julian Mackay-Wiggan16, Marc Glashofer17, Crystal Aguh18, Melissa Piliang14, Pedram Yazdan15, Kristen Lo Sicco7, James V Cassella19, Justine Koenigsberg19, Gurpreet Ahluwalia20, Eric Ghorayeb21, Steven Fakharzadeh21, Lynne Napatalung22, Kavita Gandhi22, Amy M DeLozier23, Fabio P Nunes24, Maryanne M Senna25. 1. Department of Dermatology, Yale University, New Haven, Connecticut. Electronic address: brett.king@yale.edu. 2. Department of Dermatology, University of California, Irvine, California. 3. Department of Dermatology, Yale University, New Haven, Connecticut. 4. Howard University, Washington, District of Columbia. 5. Stanford University, Stanford, California. 6. Wake Forest Baptist Health, Winston-Salem, North Carolina. 7. New York University, Langone Health, New York, New York. 8. University of California, Los Angeles, California. 9. Kaiser Permanente Vallejo Medical Center, Vallejo, California. 10. University of Miami, Miami, Florida. 11. University of Minnesota, Minneapolis, Minnesota. 12. Brigham and Women's Hospital, Boston, Massachusetts. 13. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 14. Cleveland Clinic, Cleveland, Ohio. 15. Northwestern University, Evanston, Illinois. 16. Columbia University, New York, New York. 17. The Dermatology Group, West Orange, New Jersey. 18. Johns Hopkins University, Baltimore, Maryland. 19. Concert Pharmaceuticals Inc, Lexington, Massachusetts. 20. Arena Pharmaceuticals Inc, San Diego, California. 21. Janssen Global Services, LLC, Horsham, Pennsylvania. 22. Pfizer, New York, New York. 23. Eli Lilly and Company, Indianapolis, Indiana. 24. Janssen Global Services, LLC, Horsham, Pennsylvania; Eli Lilly and Company, Indianapolis, Indiana. 25. Dermatology Associates, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: msenna@partners.org.
Abstract
BACKGROUND: The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity. OBJECTIVE: To develop an AA severity scale based on expert experience. METHODS: A modified Delphi process was utilized. An advisory group of 22 AA clinical experts from the United States was formed to develop this AA scale. Representatives from the pharmaceutical industry provided feedback during its development. RESULTS: Survey responses were used to draft severity criteria, aspiring to develop a simple scale that may be easily applied in clinical practice. A consensus vote was held to determine the final AA severity statement, with all AA experts agreeing to adopt the proposed scale. LIMITATIONS: The scale is a static assessment intended to be used in clinical practice and not clinical trials. CONCLUSION: The final AA disease severity scale, anchored in the extent of hair loss, captures key features commonly used by AA experts in clinical practice. This scale will better aid clinicians in appropriately assessing severity in patients with this common disease.
BACKGROUND: The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity. OBJECTIVE: To develop an AA severity scale based on expert experience. METHODS: A modified Delphi process was utilized. An advisory group of 22 AA clinical experts from the United States was formed to develop this AA scale. Representatives from the pharmaceutical industry provided feedback during its development. RESULTS: Survey responses were used to draft severity criteria, aspiring to develop a simple scale that may be easily applied in clinical practice. A consensus vote was held to determine the final AA severity statement, with all AA experts agreeing to adopt the proposed scale. LIMITATIONS: The scale is a static assessment intended to be used in clinical practice and not clinical trials. CONCLUSION: The final AA disease severity scale, anchored in the extent of hair loss, captures key features commonly used by AA experts in clinical practice. This scale will better aid clinicians in appropriately assessing severity in patients with this common disease.
Authors: Brett A King; Maryanne M Senna; Manabu Ohyama; Antonella Tosti; Rodney D Sinclair; Susan Ball; Justin M Ko; Marc Glashofer; Rodrigo Pirmez; Jerry Shapiro Journal: Dermatol Ther (Heidelb) Date: 2022-03-31